We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-22.69%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$116M
AUM Growth
+$3.75M
Cap. Flow
+$28.9M
Cap. Flow %
24.95%
Top 10 Hldgs %
40.13%
Holding
97
New
21
Increased
22
Reduced
11
Closed
4

Top Buys

Rank Stock Value
1
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$5.4M
2
DERM
Dermira, Inc.
DERM
+$4.22M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$3.03M
4
NVAX icon
Novavax
NVAX
+$2.97M
5
ALDR
Alder Biopharmaceuticals
ALDR
+$2.83M

Top Sells

Rank Stock Value
1
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$3.93M
2
CYTR
CytRx Corp
CYTR
+$1.54M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$725K
4
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$596K
5
LOXO
Loxo Oncology, Inc
LOXO
+$476K

Sector Composition

Rank Sector Weight
1 Healthcare 73.46%
2 Financials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXAC
51
DELISTED
Exactech Inc
EXAC
$641K 0.55%
31,636
– –
PDSB icon
52
PDS Biotechnology
PDSB
$38.8M
$633K 0.55%
+3,459
New +$618K
SCYX icon
53
SCYNEXIS
SCYX
$41M
$632K 0.55%
1,961
– –
ELOS
54
DELISTED
Syneron Medical Ltd
ELOS
$628K 0.54%
85,947
– –
AKBA icon
55
Akebia Therapeutics
AKBA
$351M
$592K 0.51%
+65,700
New +$533K
ONC
56
BeOne Medicines Ltd
ONC
$32.5B
$586K 0.51%
+20,000
New +$567K
BLUE
57
DELISTED
bluebird bio
BLUE
$510K 0.44%
926
+463
+100% +$284K
CRDC
58
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$499K 0.43%
140,275
-1
-0% -$3
INDP icon
59
Indaptus Therapeutics
INDP
$180M
$491K 0.42%
53
– –
ABUS icon
60
Arbutus Biopharma
ABUS
$847M
$476K 0.41%
+115,230
New +$412K
ABEO icon
61
Abeona Therapeutics
ABEO
$357M
$465K 0.4%
7,273
– –
BCRX icon
62
BioCryst Pharmaceuticals
BCRX
$2.28B
$423K 0.36%
149,642
-106,000
-41% -$470K
NEOS
63
DELISTED
Neos Therapeutics, Inc
NEOS
$419K 0.36%
38,873
-24,527
-39% -$259K
CYTK icon
64
Cytokinetics
CYTK
$10.6B
$392K 0.34%
55,600
+15,600
+39% +$114K
CGNT
65
DELISTED
Cogentix Medical, Inc.
CGNT
$388K 0.33%
352,882
+1,101
+0.3% +$1.24K
VTVT icon
66
vTv Therapeutics
VTVT
$125M
$377K 0.33%
1,825
– –
TNDM icon
67
Tandem Diabetes Care
TNDM
$1.3B
$318K 0.27%
3,655
– –
MBAI
68
Check-Cap
MBAI
$7.96M
$245K 0.21%
372
-83
-18% -$51.3K
VIRX
69
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$229K 0.2%
+2,016
New +$306K
RIOT icon
70
Riot Platforms
RIOT
$7.74B
$201K 0.17%
74,350
– –
MBOT icon
71
Microbot Medical
MBOT
$115M
$182K 0.16%
+432
New +$228K
AFMD
72
DELISTED
Affimed
AFMD
$175K 0.15%
+4,670
New +$176K
TENX icon
73
Tenax Therapeutics
TENX
$387M
$163K 0.14%
2
– –
TMBR
74
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$160K 0.14%
+10
New +$226K
GYRE icon
75
Gyre Therapeutics
GYRE
$635M
$119K 0.1%
630
– –
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, DAFNA Capital Management held 97 positions worth $116M, up 3.3% from $112M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

DAFNA Capital Management deployed $28.9M of net new capital in Q1 2016, opening 21 new positions and adding to 22 existing holdings. Its largest new stake was Dermira, Inc.: 171,881 shares worth $3.55M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 77% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Tobira Therapeutics, Inc. Common Stock, an estimated $596K trimmed.

  • DAFNA Capital Management's largest Q1 2016 buy was Dermira, Inc.: 171,881 shares worth $3.55M.
  • DAFNA Capital Management added most to VITAE PHARMACEUTICALS INC COMMON STOCK in Q1 2016, an estimated $5.4M increase.
  • DAFNA Capital Management's biggest Q1 2016 reduction was Tobira Therapeutics, Inc. Common Stock, cutting an estimated $596K.
  • DAFNA Capital Management fully exited CTI BioPharma Corp. (DE) Common Stock in Q1 2016, selling an estimated $3.93M.
  • DAFNA Capital Management's ten largest holdings make up 40% of its $116M portfolio in Q1 2016.
  • DAFNA Capital Management opened 21 new positions and closed 4 in Q1 2016.
  • DAFNA Capital Management's portfolio value rose 3.3% quarter-over-quarter to $116M.

Based on DAFNA Capital Management's 13F filing for Q1 2016, filed 16 May 2016.